Fernando Aprile García

Fernando Aprile García

Unlocking the Future of Medicine: The Promise and Techniques of Allogeneic Stem Cell Therapies

Linkedin Facebook X-twitter Instagram Stem cell technologies are responsible for some of the most exciting areas of modern healthcare. A core element of this is the use of allogeneic stem cell therapy in regenerative medicine. These therapies use donor-derived somatic cells, which are dedifferentiated into induced pluripotent stem cells (iPSC). From here, iPSCs can be […]

Unlocking the Future of Medicine: The Promise and Techniques of Allogeneic Stem Cell Therapies Read More »

Therapeutic Potential of iPSC-derived Allogeneic Cell Therapies: A Game Changer in Regenerative Medicine

Linkedin Facebook X-twitter Instagram Induced pluripotent stem cells (iPSCs) are revolutionizing biomedical research and healthcare by enabling the generation and modification of virtually any cell type to suit various applications. iPSCs are used for disease modeling, drug discovery, and personalized medicine, and the therapeutic potential of iPSCs is vast. Allogeneic cell therapies using iPSCs allow

Therapeutic Potential of iPSC-derived Allogeneic Cell Therapies: A Game Changer in Regenerative Medicine Read More »

Streamlining Monoclonal Antibody Production: From Quality Control to Cost Management

Linkedin Facebook X-twitter Instagram Streamlining Monoclonal Antibody Production: From Quality Control to Cost Management Monoclonal antibody production is a critical process in modern medicine, supporting the development of therapeutics that have proven invaluable across oncology, immunology, and virology (Mekala et al., 2024). Ensuring high-quality and cost-effective production involves rigorous quality control, optimizing production workflows, and

Streamlining Monoclonal Antibody Production: From Quality Control to Cost Management Read More »

Therapeutic Monoclonal Antibody Applications

Linkedin Facebook X-twitter Instagram Therapeutic Monoclonal Antibody Applications Monoclonal antibodies are highly specific antibodies designed to bind to a particular epitope on an antigen with high affinity (Castelli et al., 2019). Monoclonal antibodies are produced using hybridoma technology or Chinese Hamster Ovary (CHO) cells. Hybridoma technology was introduced by Köhler and Milstein in 1975 and

Therapeutic Monoclonal Antibody Applications Read More »

Cell Line Development: Comprehensive Insights and Advances

Linkedin Facebook X-twitter Instagram Cell Line Development: Comprehensive Insights and Advances Cell line development is a cornerstone of several modern biomedical applications. It provides essential models for studying diseases and tools for developing the latest therapeutic products1. Researchers leverage the unique benefits of mammalian cell lines and innovations in gene editing, such as clustered regularly

Cell Line Development: Comprehensive Insights and Advances Read More »

Maximizing Efficiency in Cell Line Development: Techniques and Tips

Linkedin Facebook X-twitter Instagram Maximizing Efficiency in Cell Line Development: Techniques and Tips Cell line development is essential for producing many modern therapies, including complex molecules and cell-based therapies1. New automation and genetic engineering technologies have made cell line development increasingly competitive. This acceleration in capabilities allows companies to bring novel therapeutics to market more

Maximizing Efficiency in Cell Line Development: Techniques and Tips Read More »